Stockholm Corporate Finance acted as the financial advisor for AcuCort’s rights issue of approximately SEK 47.7 million.

The rights issue was conducted in January 2025 and was oversubscribed by 160.6%.

It comprised of 7,944,670 units at a subscription price of SEK 6.00 per unit, corresponding to SEK 0.50 per share. Each unit contained 12 shares and 4 warrants.

Among the major investors were Life Science Invest Fund and Norlite AB, which made significant investments.

The capital raised will be used to support the continued commercialization of Zeqmelit® in European and U.S. markets.

About AcuCort

AcuCort is an innovative pharmaceutical company that develops and commercializes Zeqmelit®, a fast-dissolving oral film based on the corticosteroid dexamethasone.

The medication is used for the treatment of severe and acute allergic reactions, croup in children, and nausea related to chemotherapy. Zeqmelit® has been approved in Sweden, Denmark, Norway, and Finland, and sales have commenced in the Nordic region through the distribution partner Unimedic.

Investment Highlights

🔹 COMMERCIALIZATION UNDERWAY
A global commercialization effort has begun, and market approval has been granted for Zeqmelit® across Scandinavia and Finland. Applications for other key markets are in progress, with U.S. approval—by far the largest market—expected in 2024. In already approved markets, Zeqmelit® has been launched and is now available in pharmacies.

🔹 WELL-POSITIONED IN A GROWING MARKET
The global corticosteroid market is valued at over USD 5.7 billion and is expected to continue its strong growth due to increasing prevalence and population growth. With a growing number of market approvals, the establishment of key distribution and manufacturing networks, and a competitive solution, the company is well-positioned for global market penetration.

🔹 EXPERIENCED MANAGEMENT WITH EXTENSIVE EXPERTISE
The company’s leadership and board bring significant experience from the pharmaceutical industry. CEO Jonas Jönmark, in position since 2020, has held leadership roles at reputable companies such as Pfizer and AstraZeneca, building extensive expertise in international business development and product launches. Chairman of the Board, Ebba Fåhraeus, has many years of experience working with business and growth strategies across multiple life science companies.

🔹 BROAD INTELLECTUAL PROPERTY PORTFOLIO
AcuCort continuously expands its portfolio of patents and trademark protections across key global markets. Zeqmelit® is currently patented in over 35 countries, covering both the oral film technology with steroids and the production process.

🔹 MULTIPLE UPCOMING MILESTONES
The company's Phase IV study, initiated in Q1 2024, will run alongside the Nordic market launch and is a key part of the commercialization strategy in the region. In Q3 2024, Zeqmelit® was launched in pharmacies across Sweden, Norway, and Finland, with further launches expected in additional countries. The company also anticipates receiving approval for supplementary information in its U.S. regulatory application soon, along with a newly communicated registration date.